Project Details
Description
The main objective of this study is to follow trends in FQ resistance (based on the presence of gyrA/B mutations in sputum extracts) in previous molecular surveys for rifampicin resistance in Bangladesh among new TB patients.
The secondary objective is to assess whether patients with baseline FQ resistance without baseline rifampicin resistance experience higher rates of failure due to acquired resistance to non-FQ TB drugs (including rifampicin), as an indication of a clinically relevant higher mutation rate due to gyrA/B malfunction.
The secondary objective is to assess whether patients with baseline FQ resistance without baseline rifampicin resistance experience higher rates of failure due to acquired resistance to non-FQ TB drugs (including rifampicin), as an indication of a clinically relevant higher mutation rate due to gyrA/B malfunction.
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/17 → 31/12/18 |
Funding
- Damien Foundation Belgium: €52,685.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.